Patents Assigned to Galderma Laboratories, Inc.
-
Publication number: 20190091244Abstract: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.Type: ApplicationFiled: August 1, 2018Publication date: March 28, 2019Applicant: GALDERMA LABORATORIES, INC.Inventor: Robert A. ASHLEY
-
Patent number: 10058564Abstract: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.Type: GrantFiled: January 22, 2016Date of Patent: August 28, 2018Assignee: Galderma Laboratories Inc.Inventor: Robert A. Ashley
-
Patent number: 9744168Abstract: The present invention relates to a method of reducing cutaneous facial flushing caused by systemic use of phosphodiesterase type 5 (PDE5) inhibitors by topical facial dermatological application of an effective dose of a composition comprising at least one alpha adrenergic receptor agonist.Type: GrantFiled: October 12, 2012Date of Patent: August 29, 2017Assignee: GALDERMA LABORATORIES, INC.Inventors: Warren J. Scherer, Arthur Clapp, Philippe Andres
-
Patent number: 9241946Abstract: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.Type: GrantFiled: June 29, 2015Date of Patent: January 26, 2016Assignee: GALDERMA LABORATORIES INC.Inventor: Robert A. Ashley
-
Publication number: 20150031700Abstract: The present invention relates to a method of treating, reducing, inhibiting, preventing and/or reversing cutaneous facial flushing caused by abnormal, endogenously-induced vasomotor instability associated with, but not limited to acne rosacea, menopause-associated hot flashes, hot flashes resulting from orchiectomy or ingestion of substances capable of inducing a cutaneous facial flushing reaction (e.g.: alcohol, chocolate, spices) by topical dermatological application of an effective dose of a composition comprising at least one ?2 adrenergic receptor agonist (such as a (2-imidazolin-2-ylamino) quinoxaline derivative such as brimonidine tartrate)and a suitable carrier.Type: ApplicationFiled: October 14, 2014Publication date: January 29, 2015Applicant: GALDERMA LABORATORIES INC.Inventor: Warren J. Scherer
-
Patent number: 8859551Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.Type: GrantFiled: February 25, 2013Date of Patent: October 14, 2014Assignee: Galderma Laboratories Inc.Inventors: Jack A. DeJovin, Isabelle Jean DeJovin
-
Publication number: 20140100200Abstract: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.Type: ApplicationFiled: December 9, 2013Publication date: April 10, 2014Applicant: Galderma Laboratories, Inc.Inventor: Robert A. Ashley
-
Publication number: 20140100232Abstract: The invention relates to a method of treating erythema and/or telangiectasia associated with rosacea in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the site of erythema and/or telangiectasia on the skin of the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 9, 2013Publication date: April 10, 2014Applicant: Galderma Laboratories Inc.Inventors: Michael Graeber, Matthew James Leoni, Nathalie Wagner
-
Publication number: 20140094470Abstract: The invention relates to a method of treating dermatological conditions or symptoms associated therewith in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the affected area of skin on the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 10, 2013Publication date: April 3, 2014Applicant: Galderma Laboratories Inc.Inventors: Michael Graeber, Matthew James Leoni, Nathalie Wagner
-
Publication number: 20140080836Abstract: Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one ?-adrenergic receptor agonist and a pharmaceutically acceptable carrier.Type: ApplicationFiled: November 19, 2013Publication date: March 20, 2014Applicant: GALDERMA LABORATORIES INC.Inventors: Michael GRAEBER, Christian LOESCHE, Philip FREIDENREICH, Jack A. DEJOVIN, Isabelle Jean DEJOVIN, Yin-sang LIU, Matthew James LEONI
-
Patent number: 8658189Abstract: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.Type: GrantFiled: March 15, 2013Date of Patent: February 25, 2014Assignee: Galderma Laboratories, Inc.Inventor: Robert A. Ashley
-
Patent number: 8603506Abstract: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.Type: GrantFiled: October 20, 2011Date of Patent: December 10, 2013Assignee: Galderma Laboratories, Inc.Inventor: Robert A. Ashley
-
Patent number: 8586586Abstract: Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one ?-adrenergic receptor agonist and a pharmaceutically acceptable carrier.Type: GrantFiled: March 8, 2013Date of Patent: November 19, 2013Assignee: Galderma Laboratories Inc.Inventors: Michael Graeber, Christian Loesche, Philip Freidenreich, Jack A. DeJovin, Isabelle Jean DeJovin, Yin-sang Liu, Matthew James Leoni
-
Patent number: 8557817Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.Type: GrantFiled: July 10, 2012Date of Patent: October 15, 2013Assignee: Galderma Laboratories Inc.Inventors: Jack A. DeJovin, Isabelle Jean DeJovin
-
Publication number: 20130243837Abstract: Methods, compounds, and topical formulations for reduction of skin sagging, creasing and/or wrinkling are disclosed. The methods comprise topically applying a composition comprising an ?2 adrenergic receptor agonist. Amelioration of skin sagging, creasing and/or wrinkling begins within minutes after topical application of a disclosed composition. A single application can significantly reduce skin sagging, creasing and/or wrinkling for at least about 8 hours.Type: ApplicationFiled: April 15, 2013Publication date: September 19, 2013Applicant: Galderma Laboratories Inc.Inventors: Jack DeJovin, Isabelle Jean DeJovin
-
Publication number: 20130203859Abstract: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.Type: ApplicationFiled: March 15, 2013Publication date: August 8, 2013Applicant: GALDERMA LABORATORIES, INC.Inventor: GALDERMA LABORATORIES, INC.
-
Publication number: 20130197003Abstract: Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one ?-adrenergic receptor agonist and a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 8, 2013Publication date: August 1, 2013Applicant: GALDERMA LABORATORIES, INC.Inventor: GALDERMA LABORATORIES, INC.
-
Publication number: 20130172359Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.Type: ApplicationFiled: February 25, 2013Publication date: July 4, 2013Applicant: GALDERMA LABORATORIES INC.Inventor: Galderma Laboratories Inc.
-
Publication number: 20130172358Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.Type: ApplicationFiled: February 25, 2013Publication date: July 4, 2013Applicant: GALDERMA LABORATORIES INC.Inventor: GALDERMA LABORATORIES INC.
-
Patent number: 8440688Abstract: Methods, compounds, and topical formulations for reduction of skin sagging, creasing and/or wrinkling are disclosed. The methods comprise topically applying a composition comprising an ?2 adrenergic receptor agonist. Amelioration of skin sagging, creasing and/or wrinkling begins within minutes after topical application of a disclosed composition. A single application can significantly reduce skin sagging, creasing and/or wrinkling for at least about 8 hours.Type: GrantFiled: August 2, 2011Date of Patent: May 14, 2013Assignee: Galderma Laboratories Inc.Inventors: Jack DeJovin, Isabelle Jean DeJovin